Immunovant Company Insiders

Immunovant Management Team Effectiveness

The company has return on total asset (ROA) of (0.4133) % which means that it has lost $0.4133 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.6935) %, meaning that it created substantial loss on money invested by shareholders. Immunovant's management efficiency ratios could be used to measure how well Immunovant manages its routine affairs as well as how well it operates its assets and liabilities. Immunovant has a total of 203.53 Million outstanding shares. Over half of Immunovant's outstanding shares are owned by outside corporations. These outside corporations are typically referred to as corporate investors that purchase positions in a given instrument to benefit from reduced trade commissions. Also note that almost twenty-three million sixty thousand one hundred ninety-six invesors are currently shorting Immunovant expressing very little confidence in its future performance.

Immunovant Workforce Comparison

Immunovant Insider Trading

Immunovant Notable Stakeholders

String symbol = request.getParameter("s");

The success or failure of an entity such as Immunovant often depends on how effective the management is. Immunovant management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Immunovant management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Immunovant management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.

Please note, the imprecision that can be found in Immunovant's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Immunovant. Check Immunovant's Beneish M Score to see the likelihood of Immunovant's management manipulating its earnings.

When running Immunovant's price analysis, check to measure Immunovant's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Immunovant is operating at the current time. Most of Immunovant's value examination focuses on studying past and present price action to predict the probability of Immunovant's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Immunovant's price. Additionally, you may evaluate how the addition of Immunovant to your portfolios can decrease your overall portfolio volatility.